Adamas Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ADS-5102 · Neurology
  ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements.

Phase 2 pipeline

• ADS-8902
  ADAMS-8902's mechanism of action is currently under investigation and not fully characterized.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Adamas Pharmaceuticals, Inc. portfolio CI brief
• Adamas Pharmaceuticals, Inc. pipeline updates RSS